Appili Therapeutics (OTCMKTS:APLIF – Get Free Report) posted its earnings results on Thursday. The company reported ($0.01) earnings per share for the quarter, Zacks reports.
Appili Therapeutics Stock Performance
Shares of APLIF traded down $0.00 during mid-day trading on Thursday, hitting $0.01. 10,000 shares of the stock were exchanged, compared to its average volume of 51,217. The company has a market cap of $1.85 million, a PE ratio of -0.72 and a beta of -0.28. Appili Therapeutics has a 52-week low of $0.01 and a 52-week high of $0.03. The firm has a 50-day moving average of $0.02 and a two-hundred day moving average of $0.02.
About Appili Therapeutics
Appili Therapeutics Inc is a clinical-stage pharmaceutical company headquartered in Vancouver, Canada. The company specializes in the development and commercialization of novel anti-infective therapies designed to address both endemic and emerging infectious disease threats. Appili’s strategic focus includes small-molecule antibiotics, antivirals and vaccine adjuvants, with an emphasis on formulations suitable for rapid deployment in resource-limited or outbreak settings.
Appili’s product pipeline features multiple candidates in various stages of development.
Featured Stories
- Five stocks we like better than Appili Therapeutics
- When to buy gold (mathematically)
- What a Former CIA Agent Knows About the Coming Collapse
- USAU: The U.S. Gold-Copper Story Investors Can’t Ignore.
- My Epstein Story
- Think You Missed Silver? You’re Wrong. Here’s Why.
Receive News & Ratings for Appili Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Appili Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
